TSL2109 Safety and Effectiveness Study in Advanced Cancers
Part of Cancer, Kidney & urinary clinical trials.
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced cancer (solid tumor) that has spread or isn't responding to standard treatment, or standard treatment isn't available or suitable for you
- You have at least one measurable tumor that can be seen on imaging scans
- You are expected to live at least 3 months
- You are in good overall health (able to do light activities; ECOG score 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two experimental drugs, HRS-2189 and HRS-5041, for men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The goal is to see if the combination is safe and effective in controlling tumor growth.
This trial tests a new drug called SRT-017 for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The drug targets a marker on cancer cells (PSMA) and may help slow the disease. The study will check if it is safe and effective.
This study tests a new drug called HLX3902 in patients with advanced cancers that have stopped responding to standard treatments. The drug targets a protein called STEAP1 and may help slow or stop cancer growth.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This trial tests a new drug called QLS2401 for patients with advanced prostate cancer that has spread and no longer responds to standard treatments. The goal is to see if it can help control the cancer.
Hear when a new Metastatic Castration-Resistant Prostate Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.